Cardio Diagnostics Holdings, Inc.
CDIOHealthcare|Biotechnology|US
$1.65
-0.02 (-1.43%)
DCF Value
$2.24
Tangible Book / Share
$1.93
Cash / Share
$1.33
About
Cardio Diagnostics Holdings, Inc. specializes in creating and bringing to market advanced clinical diagnostic tools that leverage epigenetic insights to address cardiovascular disease. Among their key offerings is Epi+Gen CHD, a test designed to assess an individual's three-year risk for developing symptomatic coronary heart disease. This company, headquartered in Chicago, Illinois, was established in 2017.
Stock Price
-55.6%(1Y)
1M
-11.2%
3M
-7.8%
6M
-9.8%
YTD
-39.1%
1Y
-57.2%
3Y
-96.0%
5Y
-99.4%
Pipeline Summary
0 total trials0
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
Key Facts
Market Cap$4.9M
Employees15 (+15% YoY)
CEOMeeshanthini V. Dogan
IPO DateJan 14, 2022
Beta2.27
52-Week Range$0.97 – $7.91
Avg Volume50,088
ExchangeNASDAQ
Websitecdio.ai
Ownership
Float95.8%
Shares Outstanding3.0M
Recent Insider Trades
Betts Wendy JAWARD
Sep 30, 20263,286 shares @ $1.90
Fung Peter KAWARD
Sep 30, 20263,286 shares @ $1.90
Intrater JamesAWARD
Sep 30, 20263,286 shares @ $1.90
Burton Paul FrederickAWARD
Sep 30, 20263,286 shares @ $1.90
Fung Peter KAWARD
Jun 30, 20262,854 shares @ $2.19
Peers
Recent News
Critical Analysis: Genmab A/S (NASDAQ:GMAB) versus Cardio Diagnostics (NASDAQ:CDIO)
Oct 19, 2026 · defenseworld.net
Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Shares Shorted: Short Interest Down 77.7% in September
Sep 28, 2026 · defenseworld.net
Cardio Diagnostics Holdings, Inc. (CDIO) Shareholder/Analyst Call Prepared Remarks Transcript
Sep 18, 2026 · seekingalpha.com
Cardio Diagnostics (NASDAQ:CDIO) & Sutro Biopharma (NASDAQ:STRO) Head-To-Head Analysis
Aug 29, 2026 · defenseworld.net
Data last updated: Nov 9, 2026, 04:01 AM